Bio Developments

© Getty Images

Insmed unveils new research platforms and capabilities

By Isabel Cameron

US biopharma Insmed has announced progress across its early-stage research programs at the company's investor and analyst event, The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More.

© Getty Images

iOnctura reveals new translational cancer research

By Isabel Cameron

iOnctura, a clinical stage biotech company developing breakthrough therapies for cancer, has announced the peer-reviewed publication of translational research on the novel autotaxin (ATX) inhibitor IOA-289.

Pic:getty/libredroit

Genmab expands immunology reach in argenx pact

By Jonathan Smith

In a move to increase its presence in immunology and inflammation, the Danish biotech Genmab has launched a collaboration with argenx in the Netherlands to co-discover and co-develop antibody treatments.

Pic:getty/aydinmutlu

Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda

By Rachel Arthur

An mRNA cancer vaccine, in combination with Keytruda, reduced the risk of recurrence or death in melanoma patients by 44% compared to Keytruda alone, according to Phase 2b data. Merck and Moderna plan to initiate a Phase 3 study in the coming months.

Pic:getty/gilnature

Merck to acquire Prometheus Biosciences for $10.8bn

By Rachel Arthur

Merck will acquire Prometheus Biosciences, a San Diego biotech working on a precision medicine approach for developing therapeutics for the treatment of immune-mediated diseases.

Pic:getty

Samsung Ventures invests in Araris Biotech in emerging ADC strategy

By Jonathan Smith

Samsung Ventures, the global investment arm of Samsung Group, has invested an undisclosed amount in the Swiss company Araris Biotech. The deal is independent from Araris’ ongoing Series A fundraising and will be used to bankroll the development of antibody-drug...

Follow us

Webinars